DK0654037T3 - Enantiomere anti-retrovirus-nukleotidanaloger - Google Patents
Enantiomere anti-retrovirus-nukleotidanalogerInfo
- Publication number
- DK0654037T3 DK0654037T3 DK93918659T DK93918659T DK0654037T3 DK 0654037 T3 DK0654037 T3 DK 0654037T3 DK 93918659 T DK93918659 T DK 93918659T DK 93918659 T DK93918659 T DK 93918659T DK 0654037 T3 DK0654037 T3 DK 0654037T3
- Authority
- DK
- Denmark
- Prior art keywords
- enantiomeric
- nucleotide analogues
- retroviral nucleotide
- compounds
- retroviral
- Prior art date
Links
- 230000000798 anti-retroviral effect Effects 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6521—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/925,610 US6057305A (en) | 1992-08-05 | 1992-08-05 | Antiretroviral enantiomeric nucleotide analogs |
| PCT/US1993/007360 WO1994003467A2 (en) | 1992-08-05 | 1993-08-04 | Antiretroviral enantiomeric nucleotide analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0654037T3 true DK0654037T3 (da) | 1999-11-01 |
Family
ID=25451994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93918659T DK0654037T3 (da) | 1992-08-05 | 1993-08-04 | Enantiomere anti-retrovirus-nukleotidanaloger |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6057305A (cs) |
| EP (2) | EP0897917A1 (cs) |
| JP (2) | JP4083691B2 (cs) |
| AT (1) | ATE179983T1 (cs) |
| CA (2) | CA2141589C (cs) |
| CZ (2) | CZ293533B6 (cs) |
| DE (1) | DE69324923T2 (cs) |
| DK (1) | DK0654037T3 (cs) |
| ES (1) | ES2131116T3 (cs) |
| GR (1) | GR3030754T3 (cs) |
| SG (1) | SG47761A1 (cs) |
| WO (1) | WO1994003467A2 (cs) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| JPH09506333A (ja) * | 1993-09-17 | 1997-06-24 | ギリアード サイエンシーズ，インコーポレイテッド | 治療化合物の投薬方法 |
| IT1270008B (it) * | 1994-09-23 | 1997-04-16 | Ist Superiore Sanita | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| WO1997000262A1 (fr) * | 1995-06-15 | 1997-01-03 | Mitsubishi Chemical Corporation | Nucleotides derives de phosphonates |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| CN101239989B (zh) * | 1996-07-26 | 2012-12-12 | 吉联亚科学股份有限公司 | 核苷酸类似物 |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE69829010T2 (de) * | 1997-07-25 | 2006-04-13 | Gilead Sciences, Inc., Foster City | Nukleotid-Analog Zusamensetzung und Synthese Verfahren |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| EP1243593B1 (en) * | 1997-07-25 | 2005-09-21 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU9016998A (en) | 1997-08-08 | 1999-03-01 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
| US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| EP1167972B1 (en) | 1998-01-23 | 2017-03-08 | Kiadis Pharma Intellectual Property B.V. | Enzyme catalyzed therapeutic agents |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| JP2003525866A (ja) | 1999-07-22 | 2003-09-02 | ニューバイオティックス インコーポレイテッド | 治療抵抗性腫瘍を処置するための方法 |
| US20020132819A1 (en) * | 1999-12-17 | 2002-09-19 | Metcalf Chester A. | Novel purinse |
| ES2536972T5 (es) | 2000-07-21 | 2022-04-06 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos |
| CA2441350A1 (en) | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
| NZ530685A (en) | 2001-06-29 | 2006-09-29 | Acad Of Science Czech Republic | 6-'2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity |
| WO2003028737A1 (en) * | 2001-08-30 | 2003-04-10 | Mitsubishi Pharma Corporation | Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon |
| US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| IL161901A0 (en) * | 2001-11-14 | 2005-11-20 | Biocryst Pharmaceuticals Inc A | Nucleosides, preparation thereof and use as inhibiDevice for the reading and the signalling of environmental parameters tors of rna viral polymerases |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| EP1585527A1 (en) | 2003-01-14 | 2005-10-19 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| AU2004247305B2 (en) | 2003-06-16 | 2010-02-18 | Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| WO2005090370A1 (en) * | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| UA93354C2 (ru) * | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| US8101745B2 (en) * | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| CA2606399A1 (en) * | 2005-04-25 | 2006-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| JP2009532507A (ja) | 2006-04-04 | 2009-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｐｉ３キナーゼアンタゴニスト |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20080318904A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched tenofovir |
| WO2009046448A1 (en) * | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| WO2009114870A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| AU2009277172B2 (en) * | 2008-07-02 | 2014-05-29 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2010006072A2 (en) * | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| AR094621A1 (es) | 2010-04-01 | 2015-08-19 | Idenix Pharmaceuticals Inc | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN104203275A (zh) | 2010-06-09 | 2014-12-10 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| CN103079561B (zh) | 2010-06-11 | 2015-12-02 | 吉里德科学公司 | 用于预防hsv-2传播的局部用抗病毒制剂 |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| RU2606845C2 (ru) | 2010-12-10 | 2017-01-10 | СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи | Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов |
| ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
| EP2663309B1 (en) | 2011-01-10 | 2017-03-15 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| CA2828483A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| CN103282369A (zh) * | 2011-04-08 | 2013-09-04 | 劳乐斯实验室私营有限公司 | 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物 |
| CA2835321A1 (en) | 2011-05-10 | 2012-11-15 | Okapi Sciences Nv | Compounds for use in the treatment of feline retroviral infections |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| WO2013072745A1 (en) | 2011-11-16 | 2013-05-23 | Laurus Labs Private Limited | Process for the preparation of tenofovir |
| EP2794624B1 (en) * | 2011-12-22 | 2019-05-15 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| WO2014052669A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| BR112015023705A8 (pt) | 2013-03-15 | 2020-03-17 | Univ California | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN104230934B (zh) * | 2013-06-08 | 2016-12-28 | 上海医药工业研究院 | 一种化合物及其制备方法和用途 |
| EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN103641857B (zh) * | 2013-12-20 | 2016-08-24 | 石药集团中诺药业（石家庄）有限公司 | 一种替诺福韦新晶型及其制备方法 |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| BR112017005111B1 (pt) | 2014-09-15 | 2023-02-14 | The Regents Of The University Of California | Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
| MX390633B (es) | 2015-09-14 | 2025-03-04 | Infinity Pharmaceuticals Inc | Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas. |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN115677774B (zh) * | 2021-07-23 | 2025-04-22 | 上海医药工业研究院有限公司 | 膦酸酯衍生物及其制备方法和用途 |
| IL318465A (en) | 2022-07-21 | 2025-03-01 | Antiva Biosciences Inc | Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB544419A (en) * | 1940-01-08 | 1942-04-13 | Union Special Machine Co | Improvements in or relating to sewing machines |
| GB1544419A (en) * | 1975-11-19 | 1979-04-19 | Science Union & Cie | Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them |
| US4221910A (en) * | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| NL8420134A (nl) * | 1983-05-24 | 1985-04-01 | Stanford Res Inst Int | Nieuwe antivirusmiddelen. |
| PT78769A (en) * | 1983-06-24 | 1984-07-01 | Merck & Co Inc | Process for preparing (s)-9-(2,3-dihydroxy-1-propoxymethyl)guanine and derivatives thereof useful as antiviral agents |
| US4556727A (en) * | 1984-07-18 | 1985-12-03 | University Patents, Inc. | Ferroelectric smectic liquid crystals |
| CS263952B1 (en) * | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| EP0264106B1 (en) * | 1986-10-14 | 1994-03-16 | Banyu Pharmaceutical Co., Ltd. | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use |
| AU613592B2 (en) * | 1986-11-18 | 1991-08-08 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosophonomethoxy-alkyene purine and pyrimide derivatives |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| DE3883070T2 (de) * | 1987-05-18 | 1994-01-27 | Canon Kk | Polymer-Flüssigkristallzusammensetzung und Flüssigkristallvorrichtung. |
| JP2580205B2 (ja) * | 1987-10-21 | 1997-02-12 | チッソ株式会社 | 光学活性−２−ビフェニリルピリジン類 |
| NO172846C (no) * | 1987-12-25 | 1993-09-15 | Daiichi Seiyaku Co | Fremgangsmaate for fremstilling av 7,8-dihalogen-3-metyl-2,3-dihydro-2m-benzoksazinderivater og propoksybenzenderivater for utoevelse av fremgangsmaaten. |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| AU4376589A (en) * | 1988-11-07 | 1990-05-10 | Gist-Brocades N.V. | Optically active benzoxazines and benzothiazines |
| DE3906357A1 (de) * | 1989-03-01 | 1990-09-06 | Boehringer Mannheim Gmbh | Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| FI911875A7 (fi) * | 1990-04-20 | 1991-10-21 | Acad Of Science Czech Republic | Kiraaliset 2-(fosfonometoksi)propyyliguaniinit virustenvastaisina aineina |
| CZ285420B6 (cs) * | 1990-04-24 | 1999-08-11 | Ústav Organické Chemie A Biochemie Avčr | N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití |
| CS387190A3 (en) * | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof |
| KR100221981B1 (ko) * | 1990-08-10 | 1999-09-15 | 안토닌 포레이트 | 뉴클레오티드의 신규 제조방법 |
| EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| WO1995032983A1 (en) * | 1994-05-31 | 1995-12-07 | Medivir Ab | Post exposure prevention of hiv |
-
1992
- 1992-08-05 US US07/925,610 patent/US6057305A/en not_active Expired - Lifetime
-
1993
- 1993-08-04 DE DE69324923T patent/DE69324923T2/de not_active Expired - Lifetime
- 1993-08-04 CA CA002141589A patent/CA2141589C/en not_active Expired - Lifetime
- 1993-08-04 ES ES93918659T patent/ES2131116T3/es not_active Expired - Lifetime
- 1993-08-04 SG SG1996004260A patent/SG47761A1/en unknown
- 1993-08-04 EP EP98119443A patent/EP0897917A1/en not_active Withdrawn
- 1993-08-04 CZ CZ2001529A patent/CZ293533B6/cs not_active IP Right Cessation
- 1993-08-04 AT AT93918659T patent/ATE179983T1/de active
- 1993-08-04 CA CA002574904A patent/CA2574904C/en not_active Expired - Lifetime
- 1993-08-04 DK DK93918659T patent/DK0654037T3/da active
- 1993-08-04 WO PCT/US1993/007360 patent/WO1994003467A2/en not_active Ceased
- 1993-08-04 US US08/379,551 patent/US6653296B1/en not_active Expired - Lifetime
- 1993-08-04 EP EP93918659A patent/EP0654037B1/en not_active Expired - Lifetime
- 1993-08-04 CZ CZ1995272A patent/CZ290797B6/cs not_active IP Right Cessation
-
1999
- 1999-07-14 GR GR990401839T patent/GR3030754T3/el unknown
-
2000
- 2000-02-08 US US09/500,148 patent/US6479673B1/en not_active Expired - Fee Related
-
2004
- 2004-02-05 JP JP2004029994A patent/JP4083691B2/ja not_active Expired - Lifetime
-
2007
- 2007-12-18 JP JP2007326607A patent/JP2008120820A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0897917A1 (en) | 1999-02-24 |
| CA2574904A1 (en) | 1994-02-17 |
| EP0654037A1 (en) | 1995-05-24 |
| US6057305A (en) | 2000-05-02 |
| JP2004189750A (ja) | 2004-07-08 |
| DE69324923T2 (de) | 1999-11-25 |
| CA2574904C (en) | 2009-06-16 |
| WO1994003467A2 (en) | 1994-02-17 |
| CZ27295A3 (en) | 1995-12-13 |
| JP2008120820A (ja) | 2008-05-29 |
| CA2141589A1 (en) | 1994-02-17 |
| JP3561272B2 (ja) | 2004-09-02 |
| SG47761A1 (en) | 1998-04-17 |
| HK1011998A1 (en) | 1999-07-23 |
| US6653296B1 (en) | 2003-11-25 |
| ES2131116T3 (es) | 1999-07-16 |
| US6479673B1 (en) | 2002-11-12 |
| JP4083691B2 (ja) | 2008-04-30 |
| ATE179983T1 (de) | 1999-05-15 |
| CA2141589C (en) | 2007-04-17 |
| CZ290797B6 (cs) | 2002-10-16 |
| JPH08503927A (ja) | 1996-04-30 |
| DE69324923D1 (de) | 1999-06-17 |
| CZ293533B6 (cs) | 2004-05-12 |
| GR3030754T3 (en) | 1999-11-30 |
| EP0654037B1 (en) | 1999-05-12 |
| WO1994003467A3 (en) | 1994-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0654037T3 (da) | Enantiomere anti-retrovirus-nukleotidanaloger | |
| ATE108452T1 (de) | Puringruppen enthaltende cyclobutane. | |
| DE69001187D1 (de) | 6-epifumagillole, ihre herstellung und ihre verwendung. | |
| GR3017812T3 (en) | 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof. | |
| NL300241I1 (nl) | Hydroxymethyl(methyleencyclopentyl)uurines en -pyrimidines. | |
| SE8500307D0 (sv) | Nya, antiviruella medel | |
| ATE167679T1 (de) | Wirkstoffvorläufer von phosphonaten | |
| ATE110382T1 (de) | Oxetanocin. | |
| ES2131730T3 (es) | Preparacion de compuestos de guanina n-9 sustituidos. | |
| ES2108016T3 (es) | Triazolopiridazinas substituidas. | |
| ES2055211T3 (es) | Purinil- y pirimidinil-tetrahidrofuranos. | |
| DE68909143D1 (de) | Prostaglandin-Vorläufer und ihre Herstellung. | |
| DE69601451D1 (de) | UCK14-Verbindungen | |
| DK0439058T3 (da) | Acycliske terpener | |
| DK0717731T3 (da) | Antivirale difluorstatonanaloge | |
| ATE53029T1 (de) | Phenylharnstoff-herbicide. |